| ČEJKOVÁ, Soňa, Ludmila ROČŇOVÁ, David POTĚŠIL, Jana ŠMARDOVÁ, Věra NOVÁKOVÁ, Jitka CHUMCHALOVÁ, Dita ŽEŽULKOVÁ, Marek BORSKÝ, Michael DOUBEK, Yvona BRYCHTOVÁ, Šárka POSPÍŠILOVÁ, Martin KLABUSAY, Jiří MAYER and Martin TRBUŠEK. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. European Journal of Haematology. 2009, vol. 82, No 2, p. 133-142. ISSN 0902-4441. Available from: https://dx.doi.org/10.1111/j.1600-0609.2008.01177.x. |
Other formats:
BibTeX
LaTeX
RIS
@article{815687,
author = {Čejková, Soňa and Ročňová, Ludmila and Potěšil, David and Šmardová, Jana and Nováková, Věra and Chumchalová, Jitka and Žežulková, Dita and Borský, Marek and Doubek, Michael and Brychtová, Yvona and Pospíšilová, Šárka and Klabusay, Martin and Mayer, Jiří and Trbušek, Martin},
article_number = {2},
doi = {http://dx.doi.org/10.1111/j.1600-0609.2008.01177.x},
keywords = {chronic lymphocytic leukemia; fludarabine; rituximab; ATM; p53},
language = {eng},
issn = {0902-4441},
journal = {European Journal of Haematology},
title = {Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine},
url = {https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0609.2008.01177.x},
volume = {82},
year = {2009}
}
TY - JOUR
ID - 815687
AU - Čejková, Soňa - Ročňová, Ludmila - Potěšil, David - Šmardová, Jana - Nováková, Věra - Chumchalová, Jitka - Žežulková, Dita - Borský, Marek - Doubek, Michael - Brychtová, Yvona - Pospíšilová, Šárka - Klabusay, Martin - Mayer, Jiří - Trbušek, Martin
PY - 2009
TI - Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine
JF - European Journal of Haematology
VL - 82
IS - 2
SP - 133-142
EP - 133-142
SN - 09024441
KW - chronic lymphocytic leukemia
KW - fludarabine
KW - rituximab
KW - ATM
KW - p53
UR - https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0609.2008.01177.x
L2 - https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0609.2008.01177.x
N2 - Objectives: Abnormalities of the TP53 or ATM, cooperating tumor-suppressor genes, significantly worsen the treatment options for chronic lymphocytic leukemia (CLL) patients. Although the aberrations seem to be mutually exclusive in this leukemia, inactivation of the former gene leads to worse prognosis. We tested the in vitro sensitivity of the CLL samples with heterozygous ATM deletion to fludarabine and combination of fludarabine and rituximab; the responses were compared with the TP53-abnormal and wild-type (wt) cells in order to delimitate relative significance of ATM deletion. Methods: In vitro analysis was performed on fifty-nine characterized CLL samples using viability assay WST-1. Western blot and real-time RT-PCR were used to monitor the activation of the ATM/p53 pathway. Results and Conclusions: At the clinically relevant concentration of fludarabine, TP53-abnormal samples exhibited markedly higher resistance to fludarabine than the remaining CLL samples (p = 0,012); cohort with ATM deletion was not more resistant than wt cells. A similar induction of the p53 protein and its downstream target genes PUMA and BAX in ATM-deleted and wt cells confirmed that the former subgroup has preserved a critical pro-apoptotic response. Proportions of the samples which had been sensitized to fludarabine by rituximab pre-treatment were insignificantly lower (p = 0.22) in the TP53-abnormal and ATM-deleted subgroups compared to the wt cases (30%; 29%; 50%, respectively). The presence of ATM (11q22-23) deletion in the CLL cells should not be considered an indication of resistance to fludarabine or its combination with rituximab.
ER -
ČEJKOVÁ, Soňa, Ludmila ROČŇOVÁ, David POTĚŠIL, Jana ŠMARDOVÁ, Věra NOVÁKOVÁ, Jitka CHUMCHALOVÁ, Dita ŽEŽULKOVÁ, Marek BORSKÝ, Michael DOUBEK, Yvona BRYCHTOVÁ, Šárka POSPÍŠILOVÁ, Martin KLABUSAY, Jiří MAYER and Martin TRBUŠEK. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine. \textit{European Journal of Haematology}. 2009, vol.~82, No~2, p.~133-142. ISSN~0902-4441. Available from: https://dx.doi.org/10.1111/j.1600-0609.2008.01177.x.
|
